目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T8372 | Potassium Channel | ||
VU 0134992 是一个亚型偏好的,口服有效的和选择性的内向整流钾通道 Kir4.1阻滞剂,IC50为 0.97 μM。在 -120 mV 时,VU0134992对同分 Kir4.1 比 Kir4.1/5.1 共分通道 (IC50=9 μM) 高出 9 倍的选择性。 | |||
T13316 | Potassium Channel | ||
VU0134992 hydrochloride 是一个亚型偏好的,具有口服活性和选择性的内向整流钾通道Kir4.1阻滞剂,IC50为 0.97 μM。在 -120 mV 时,VU0134992 hydrochloride 对同分 Kir4.1 比 Kir4.1/5.1 共分通道 (IC50=9 μM) 高出 9 倍的选择性。 | |||
T6658 | OX Receptor | ||
SB408124 是一种 OX1 受体的非肽拮抗剂,在全细胞和膜中的 Ki 值分别为 57 和 27 nM,其选择性是 OX2 受体的 50 倍。 | |||
T4367 | c-Myc Autophagy | ||
Mycro 3 在全细胞分析中对 c-Myc 具有强效选择性,可用于胰腺癌的研究。 | |||
T16383 | Guanylate cyclase | ||
Olinciguat (IW-1701) 是一种口服鸟苷酸环化酶 (sGC) 刺激剂,在纯化的大鼠和人类酶测定以及全细胞测定中对 sGC 具有浓度依赖性刺激作用。 | |||
T76870 | SARS-CoV | ||
Narsoplimab (OMS 721) 是一种选择性全人免疫球蛋白γ 4 (IgG4) 单克隆抗体,是一种甘露聚糖结合凝集素相关的丝氨酸蛋白酶-2(MASP-2)抑制剂,可结合 MASP-2 并阻止凝集素通路激活,对凝集素通路有抑制作用。Narsoplimab 可用于研究成人造血干细胞移植相关疾病。 | |||
T12844 | Others | ||
SB-408124 Hydrochloride is a non-peptide OX1 receptor antagonist(Ki of 57 nM and 27 nM in both whole cell and membrane, respectively). | |||
T61446 | |||
BioA-IN-13 is a highly effective inhibitor of the Mycobacterium tuberculosis BioA enzyme, displaying potent cell permeability and whole-cell activity [1]. | |||
T11243 | Others | ||
Gliclazide is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Ethyl tosylcarbamate is an intermediate in the synthesis of Gliclazide (G409877). | |||
T30990 | |||
CMFDA can be used as a fluorescent whole-cell-tracking reagent. |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-02306 | MAB21L2 Protein, Human, Recombinant (His & ZZ) | Human | E. coli | ||
MAB21L2 (Mab-21 Like 2) is a Protein Coding gene. It encodes a protein similar to C. elegans mab-21 cell fate-determining factor. The protein encoded by this gene is primarily nuclear, although some cytoplasmic localization has been observed. MAB21L2 belongs to the mab-21 family. It is required for several aspects of embryonic development including normal development of the eye. It is thought that this gene may also be involved in neural development. The identification of MAB21L2 as a novel factor involved in human coloboma and highlight the power of genome editing manipulation in model organisms for analysis of the effects of whole-exome variation in humans. Diseases associated with MAB21L2 include Microphthalmia/Coloboma And Skeletal Dysplasia Syndrome and Microphthalmia.
|
|||||
TMPH-03741 | BoNT/F Protein, Clostridium botulinum, Recombinant (His) | Clostridium botulinum | E. coli | ||
Botulinum toxin causes flaccid paralysis by inhibiting neurotransmitter (acetylcholine) release from the presynaptic membranes of nerve terminals of the eukaryotic host skeletal and autonomic nervous system, with frequent heart or respiratory failure. Precursor of botulinum neurotoxin F which may have 2 coreceptors; complex polysialylated gangliosides found on neural tissue and specific membrane-anchored proteins found in synaptic vesicles. Receptor proteins are exposed on host presynaptic cell membrane during neurotransmitter release, when the toxin heavy chain (HC) binds to them. Upon synaptic vesicle recycling the toxin is taken up via the endocytic pathway. When the pH of the toxin-containing endosome drops a structural rearrangement occurs so that the N-terminus of the HC forms pores that allows the light chain (LC) to translocate into the cytosol. Once in the cytosol the disulfide bond linking the 2 subunits is reduced and LC cleaves its target protein on synaptic vesicles, preventing their fusion with the cytoplasmic membrane and thus neurotransmitter release. Whole toxin only has protease activity after reduction, which releases LC. Requires complex eukaryotic host polysialogangliosides for full neurotoxicity. It is not clear whether a synaptic vesicle protein acts as its receptor; there is evidence for and against SV2 fulfilling this function.; Has proteolytic activity. After translocation into the eukaryotic host cytosol, inhibits neurotransmitter release by acting as a zinc endopeptidase that catalyzes the hydrolysis of the '60-Gln-|-Lys-61' bond of synaptobrevin-1/VAMP1 and the equivalent 'Gln-|-Lys' sites in VAMP2 and VAMP3. Cleaves the '48-Gln-|-Lys-49' bond of A.californica synaptobrevin (AC P35589).; Responsible for host epithelial cell transcytosis, host nerve cell targeting and translocation of light chain (LC) into host cytosol. Composed of 3 subdomains; the translocation domain (TD), and N-terminus and C-terminus of the receptor-binding domain (RBD). The RBD is responsible for the adherence of the toxin to the cell surface. It simultaneously recognizes 2 coreceptors; polysialated gangliosides and the receptor protein SV2A, SV2B and SV2C in close proximity on host synaptic vesicles; although not all evidence indicates these are the receptors. The N-terminus of the TD wraps an extended belt around the perimeter of the LC, protecting Zn(2+) in the active site; it may also prevent premature LC dissociation from the translocation channel and protect toxin prior to translocation. The TD inserts into synaptic vesicle membrane to allow translocation into the host cytosol.
|